Compare NTRA & ROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | ROP |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1B | 33.4B |
| IPO Year | 2015 | 2002 |
| Metric | NTRA | ROP |
|---|---|---|
| Price | $224.20 | $332.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | $259.07 | ★ $492.60 |
| AVG Volume (30 Days) | ★ 1.6M | 1.0M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ 0.65 | N/A |
| EPS | N/A | ★ 4.87 |
| Revenue | $210,939,000.00 | ★ $7,902,500,000.00 |
| Revenue This Year | $18.08 | $8.80 |
| Revenue Next Year | $19.65 | $6.73 |
| P/E Ratio | ★ N/A | $68.11 |
| Revenue Growth | N/A | ★ 12.26 |
| 52 Week Low | $131.81 | $305.96 |
| 52 Week High | $256.36 | $576.49 |
| Indicator | NTRA | ROP |
|---|---|---|
| Relative Strength Index (RSI) | 60.92 | 48.24 |
| Support Level | $186.96 | $310.28 |
| Resistance Level | $244.65 | $340.00 |
| Average True Range (ATR) | 10.42 | 9.61 |
| MACD | 2.11 | 2.11 |
| Stochastic Oscillator | 91.04 | 57.98 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Roper Technologies is a holding company focused on acquiring, managing, and developing niche market-leading technology businesses. The company operates a decentralized business model whereby each portfolio company operates independently from the others. Roper positions itself as a free cash flow compounder, whereby excess free cash flow generated by its portfolio businesses is repatriated to the parent company, which is then utilized to acquire additional businesses. Presently, the company operates 30 distinct businesses with over three-fourths of the revenue coming from software products and over two-thirds of revenue coming from recurring and reoccurring sources.